Health TrialsbyHealthPanel

Non-invasive Evaluation of the Predictive Value of CEUS and SWE in ACLF, Renal Failure and Hepatorenal Syndrome

ConditionKidney Failure, Acute
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorUniversity Hospital, Bonn

About this trial

Evaluation of non-invasive prognostic parameters in patients developing ACLF and renal failure in patients receiving and not receiving transjugular intrahepatic portosystemic shunt (TIPS). Patients are cared according to the local standardized follow up program. Clinical and laboratory data from standard patient care are evaluated for potential prognostic value.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

All patients with portal hypertension and kidney failure

Disqualifiers

no consent, no kidney failure, no portal hypertension

Trial population

All patients with portal hypertension and kidney failure are eligible for inclusion

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

1,000 Participants
are grouped into 2 trial groups
Group A: With TIPS
Group B: Without TIPS

Trial outcomes

Primary outcomes

1

Survival

death, liver transplantation

Time frame
up to 10 years

Secondary outcomes

1

Ascites

Evaluation of amount of ascites according to the Child-Score

Time frame
up to 10 years
2

Hepatic Encephalopathy

Evaluation of the grade according to the West Haven Criteria

Time frame
up to 10 years
3

Variceal Bleeding

Assessment of presence of variceal bleeding

Time frame
up to 10 years
4

Liver Failure

defined as Bilirubin level ≥ 12mg/dl

Time frame
up to 10 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Bonn

Lead sponsor

Source ClinicalTrials.gov
Apply now